JP2018521663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521663A5 JP2018521663A5 JP2018503642A JP2018503642A JP2018521663A5 JP 2018521663 A5 JP2018521663 A5 JP 2018521663A5 JP 2018503642 A JP2018503642 A JP 2018503642A JP 2018503642 A JP2018503642 A JP 2018503642A JP 2018521663 A5 JP2018521663 A5 JP 2018521663A5
- Authority
- JP
- Japan
- Prior art keywords
- immune response
- response cell
- cell according
- binding element
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 28
- 230000028993 immune response Effects 0.000 claims 24
- 230000027455 binding Effects 0.000 claims 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 108010057085 cytokine receptors Proteins 0.000 claims 3
- 102000003675 cytokine receptors Human genes 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 108091008034 costimulatory receptors Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114022A JP2021168675A (ja) | 2015-07-31 | 2021-07-09 | 治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513540.3A GB201513540D0 (en) | 2015-07-31 | 2015-07-31 | Therapeutic agents |
| GB1513540.3 | 2015-07-31 | ||
| PCT/GB2016/052324 WO2017021701A1 (en) | 2015-07-31 | 2016-07-28 | Therapeutic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114022A Division JP2021168675A (ja) | 2015-07-31 | 2021-07-09 | 治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521663A JP2018521663A (ja) | 2018-08-09 |
| JP2018521663A5 true JP2018521663A5 (cg-RX-API-DMAC7.html) | 2019-08-29 |
| JP7053037B2 JP7053037B2 (ja) | 2022-04-12 |
Family
ID=54062973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503642A Active JP7053037B2 (ja) | 2015-07-31 | 2016-07-28 | 治療薬 |
| JP2021114022A Pending JP2021168675A (ja) | 2015-07-31 | 2021-07-09 | 治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114022A Pending JP2021168675A (ja) | 2015-07-31 | 2021-07-09 | 治療薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10703794B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3328880B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7053037B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102411571B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107735407B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016303355B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2993746A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3328880T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2883633T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201513540D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256511B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018001009A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2747733C1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201912416QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017021701A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| GB201514874D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| EP3336107A1 (en) * | 2016-12-15 | 2018-06-20 | Miltenyi Biotec GmbH | Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| CN117384929A (zh) | 2017-03-27 | 2024-01-12 | 新加坡国立大学 | 一种编码由细胞表达的嵌合受体的多核苷酸 |
| EP3630132A1 (en) | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018308923A1 (en) * | 2017-07-26 | 2020-03-12 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (CAR) immune cell selection |
| CN109971724B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 靶向ErbB受体家族且自表达PD-1抗体的CAR-T细胞及其用途 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
| EP3587454A1 (en) * | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| EP3937974A1 (en) | 2019-03-11 | 2022-01-19 | Leucid Bio Ltd | Muc1 parallel car (pcar) therapeutic agents |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| JP2022545643A (ja) * | 2019-08-13 | 2022-10-28 | キングス・カレッジ・ロンドン | Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞 |
| US20220298223A1 (en) * | 2019-08-28 | 2022-09-22 | King's College London | B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS |
| GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
| US20240261404A1 (en) * | 2020-04-17 | 2024-08-08 | 2Seventy Bio, Inc. | Modified ccr polypeptides and uses thereof |
| CA3185197A1 (en) * | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2022083668A1 (en) * | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| EP4384211A1 (en) * | 2021-08-13 | 2024-06-19 | Ludwig-Maximilians-Universität München | Anti-csf1r car expressing lymphocytes for targeted tumor therapy |
| KR20240055733A (ko) * | 2021-08-18 | 2024-04-29 | 레전드 바이오테크 아일랜드 리미티드 | Tlr 수용체를 발현하는 변형된 면역 세포 |
| JP7732843B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732839B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732842B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732840B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732841B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| KR20240128679A (ko) | 2021-11-15 | 2024-08-26 | 네오진 테라퓨틱스 비.브이. | Tgf-베타 수용체 신호전달이 감소된 조작된 t 세포 |
| US20250108113A1 (en) | 2021-12-30 | 2025-04-03 | Tr1X, Inc. | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
| CN118510814A (zh) * | 2022-05-10 | 2024-08-16 | 星尘生物科技(上海)有限公司 | 一种嵌合抗原受体及其应用 |
| WO2024209084A1 (en) | 2023-04-05 | 2024-10-10 | Kings College London | Parallel chimeric antigen receptors (pcars) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof |
| GB202403718D0 (en) | 2024-03-14 | 2024-05-01 | King S College London | Therapeutic agents |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871495B1 (en) * | 1995-02-24 | 2005-06-15 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| CN114835823A (zh) | 2011-07-29 | 2022-08-02 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| EP4230647A1 (en) | 2012-02-22 | 2023-08-23 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| JP2015509716A (ja) | 2012-02-22 | 2015-04-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 第二世代キメラ抗原受容体におけるｃｄ２シグナル伝達ドメインの使用 |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| RU2663725C2 (ru) | 2012-09-04 | 2018-08-08 | Селлектис | Многоцепочечный химерный антигенный рецептор и его применения |
| AR092745A1 (es) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
| RU2729401C2 (ru) * | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| CN113005091A (zh) | 2013-02-06 | 2021-06-22 | 细胞基因公司 | 具有改进特异性的修饰的t淋巴细胞 |
| PT3300745T (pt) | 2013-02-15 | 2019-11-27 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| WO2014138348A1 (en) | 2013-03-06 | 2014-09-12 | The Trustees Of The University Of Pennsylvania | Iikaros inhibition to augment adoptive t cell transfer |
| EP2964764A1 (en) | 2013-03-09 | 2016-01-13 | Baylor College Of Medicine | Vascular-targeted t-cell therapy |
| US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
| CN105452287A (zh) | 2013-04-17 | 2016-03-30 | 贝勒医学院 | 免疫抑制性TGF-β信号转换器 |
| NZ758715A (en) | 2013-10-31 | 2023-01-27 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| MX377283B (es) | 2013-11-21 | 2025-03-07 | Ucl Business Ltd | Célula t o nk que coexpresa un receptor antigénico quimérico (car). |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| US10330390B2 (en) * | 2013-12-26 | 2019-06-25 | Verdus Technologies Pte. Ltd. | Fluid handling device and a method of heating or cooling a fluid flow |
| WO2015164627A1 (en) | 2014-04-23 | 2015-10-29 | Discovery Genomics, Inc. | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer |
| CA2954414A1 (en) * | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| ES2947589T3 (es) | 2015-01-31 | 2023-08-11 | Univ Pennsylvania | Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T |
| CN108174607A (zh) | 2015-05-29 | 2018-06-15 | 朱诺治疗学股份有限公司 | 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法 |
| GB201513540D0 (en) * | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| EP3937974A1 (en) * | 2019-03-11 | 2022-01-19 | Leucid Bio Ltd | Muc1 parallel car (pcar) therapeutic agents |
-
2015
- 2015-07-31 GB GBGB1513540.3A patent/GB201513540D0/en not_active Ceased
-
2016
- 2016-07-28 DK DK16750211.1T patent/DK3328880T3/da active
- 2016-07-28 MX MX2018001009A patent/MX2018001009A/es unknown
- 2016-07-28 CN CN201680039617.1A patent/CN107735407B/zh active Active
- 2016-07-28 US US15/749,016 patent/US10703794B2/en active Active
- 2016-07-28 RU RU2018105137A patent/RU2747733C1/ru active
- 2016-07-28 AU AU2016303355A patent/AU2016303355B2/en active Active
- 2016-07-28 CA CA2993746A patent/CA2993746A1/en active Pending
- 2016-07-28 EP EP16750211.1A patent/EP3328880B1/en active Active
- 2016-07-28 ES ES16750211T patent/ES2883633T3/es active Active
- 2016-07-28 EP EP21177321.3A patent/EP3939992A1/en not_active Withdrawn
- 2016-07-28 KR KR1020187005607A patent/KR102411571B1/ko active Active
- 2016-07-28 JP JP2018503642A patent/JP7053037B2/ja active Active
- 2016-07-28 WO PCT/GB2016/052324 patent/WO2017021701A1/en not_active Ceased
- 2016-07-28 SG SG10201912416QA patent/SG10201912416QA/en unknown
-
2017
- 2017-12-24 IL IL256511A patent/IL256511B/en unknown
-
2020
- 2020-05-18 US US16/877,035 patent/US10865231B2/en active Active
- 2020-05-18 US US16/877,008 patent/US10899818B2/en active Active
- 2020-12-10 US US17/118,045 patent/US11802143B2/en active Active
-
2021
- 2021-07-09 JP JP2021114022A patent/JP2021168675A/ja active Pending
-
2023
- 2023-09-22 US US18/472,441 patent/US20240076348A1/en active Pending